HIV-1 protease inhibitors and the MDR1 multidrug transporter.
Open Access
- 15 January 1998
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 101 (2) , 287-288
- https://doi.org/10.1172/jci2575
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapyProceedings of the National Academy of Sciences, 1997
- Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.Journal of Clinical Investigation, 1997
- Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma ViremiaScience, 1997
- Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteinsProceedings of the National Academy of Sciences, 1997
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- Is P-Glycoprotein a Sufficient Marker for Multidrug Resistance in Vivo? Immunohistochemical Staining for P-Glycoprotein in Children and Adult Leukemia: Correlation with Clinical OutcomeLeukemia & Lymphoma, 1995
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsPublished by Elsevier ,1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.1992